KCTD14 (potassium channel tetramerization domain containing 14) is a protein-binding molecule with emerging roles in cancer immunology and viral infection response. In pancreatic cancer, KCTD14 functions as an immunomodulatory oncogene enriched in malignant epithelial cells that promotes tumor progression through interaction with dendritic cells via the TNF-TNFRSF1A signaling axis 1. KCTD14 knockdown significantly reduces pancreatic cancer cell proliferation, migration, invasion, and TNF-α expression 1. Beyond pancreatic cancer, KCTD14 is a component of cancer-associated fibroblast-derived signatures that predict radiotherapy response and biochemical recurrence-free survival in prostate cancer patients 2. In ovarian cancer, KCTD14 is identified as a DNA methylation-related prognostic gene associated with patient survival prediction and immune landscape characteristics 3. KCTD14 also demonstrates consistent upregulation across dengue virus infection severity levels, suggesting a role in host immune response to viral infection 4, 5. These findings suggest KCTD14 functions at the intersection of cancer-immune cell interactions and viral pathogenesis, potentially through TNF signaling modulation. Clinical significance includes potential utility as a prognostic biomarker across multiple cancers and infectious diseases, with KCTD14/TNFR1-targeted therapies representing novel therapeutic approaches for overcoming immune suppression in cancer.